BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38403951)

  • 1. Sialic Acid Conjugate-Modified Cationic Liposomal Paclitaxel for Targeted Therapy of Lung Metastasis in Breast Cancer: What a Difference the Cation Content Makes.
    Sun W; Han C; Ge R; Jiang X; Wang Y; Han Y; Wang N; Song Y; Yang M; Chen G; Deng Y
    Mol Pharm; 2024 Apr; 21(4):1625-1638. PubMed ID: 38403951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Application of Tumor-Associated Macrophages as Immunotherapy Targets: Sialic Acid-Modified EPI-Loaded Liposomes Inhibit Breast Cancer Metastasis.
    Meng X; Wang M; Zhang K; Sui D; Chen M; Xu Z; Guo T; Liu X; Deng Y; Song Y
    AAPS PharmSciTech; 2022 Oct; 23(8):285. PubMed ID: 36258152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity.
    Zhou S; Zhang T; Peng B; Luo X; Liu X; Hu L; Liu Y; Di D; Song Y; Deng Y
    Int J Pharm; 2017 May; 523(1):203-216. PubMed ID: 28336455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sialic acid-decorated liposomes enhance the anti-cancer efficacy of docetaxel in tumor-associated macrophages.
    Tran NP; Tran P; Yoo SY; Tangchang W; Lee S; Lee JY; Son HY; Park JS
    Biomater Adv; 2023 Nov; 154():213606. PubMed ID: 37678087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal Doxorubicin: the Sphingomyelin/Cholesterol System Significantly Enhances the Antitumor Efficacy of Doxorubicin.
    Meng X; Zhang H; Chen L; Wang M; Zhang K; Liu X; Deng Y; Song Y
    AAPS PharmSciTech; 2023 Feb; 24(2):64. PubMed ID: 36759405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacodynamics of liposomes modified with different chain length of sialic acid derivatives].
    Song YZ; Huang ZJ; Luo X; Wang MJ; Zheng JH; Shi J; Deng YH
    Yao Xue Xue Bao; 2016 Feb; 51(2):316-24. PubMed ID: 29856587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Terminating the renewal of tumor-associated macrophages: A sialic acid-based targeted delivery strategy for cancer immunotherapy.
    Ding J; Zhao D; Hu Y; Liu M; Liao X; Zhao B; Liu X; Deng Y; Song Y
    Int J Pharm; 2019 Nov; 571():118706. PubMed ID: 31593811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anticancer efficacy of pixantrone-loaded liposomes decorated with sialic acid-octadecylamine conjugate.
    She Z; Zhang T; Wang X; Li X; Song Y; Cheng X; Huang Z; Deng Y
    Biomaterials; 2014 Jun; 35(19):5216-25. PubMed ID: 24703714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response.
    Jiang L; Li L; He X; Yi Q; He B; Cao J; Pan W; Gu Z
    Biomaterials; 2015 Jun; 52():126-39. PubMed ID: 25818419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyaluronic acid-coated liposomes for targeted delivery of paclitaxel, in-vitro characterization and in-vivo evaluation.
    Ravar F; Saadat E; Gholami M; Dehghankelishadi P; Mahdavi M; Azami S; Dorkoosh FA
    J Control Release; 2016 May; 229():10-22. PubMed ID: 26968799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the antitumor effect of dexamethasone palmitate and doxorubicin co-loaded liposomes modified with a sialic acid-octadecylamine conjugate.
    Sun J; Song Y; Lu M; Lin X; Liu Y; Zhou S; Su Y; Deng Y
    Eur J Pharm Sci; 2016 Oct; 93():177-83. PubMed ID: 27539143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization design of sialic acid derivatives enhances the performance of liposomes for modulating immunosuppressive tumor microenvironments.
    Sui D; Liang K; Gui Y; Du Z; Xin D; Yu G; Zhai W; Liu X; Song Y; Deng Y
    Life Sci; 2022 Dec; 310():121081. PubMed ID: 36273630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy.
    Qiu Q; Li C; Song Y; Shi T; Luo X; Zhang H; Hu L; Yan X; Zheng H; Liu M; Liu M; Liu M; Yang S; Liu X; Chen G; Deng Y
    Acta Biomater; 2019 Jul; 92():184-195. PubMed ID: 31108259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil-mediated delivery of pixantrone-loaded liposomes decorated with poly(sialic acid)-octadecylamine conjugate for lung cancer treatment.
    Luo X; Hu L; Zheng H; Liu M; Liu X; Li C; Qiu Q; Zhao Z; Cheng X; Lai C; Su Y; Deng Y; Song Y
    Drug Deliv; 2018 Nov; 25(1):1200-1212. PubMed ID: 29791241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphatidylserine and/or Sialic Acid Modified Liposomes Increase Uptake by Tumor-associated Macrophages and Enhance the Anti-tumor Effect.
    Xu Z; Li J; Yan N; Liu X; Deng Y; Song Y
    AAPS PharmSciTech; 2024 Jun; 25(5):125. PubMed ID: 38834759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sialic acid conjugate-modified liposomes enable tumor homing of epirubicin via neutrophil/monocyte infiltration for tumor therapy.
    Ding J; Sui D; Liu M; Su Y; Wang Y; Liu M; Luo X; Liu X; Deng Y; Song Y
    Acta Biomater; 2021 Oct; 134():702-715. PubMed ID: 34339869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation.
    Jiang K; Shen M; Xu W
    Int J Nanomedicine; 2018; 13():2561-2569. PubMed ID: 29731631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis.
    Chen X; Zhang Y; Tang C; Tian C; Sun Q; Su Z; Xue L; Yin Y; Ju C; Zhang C
    Int J Pharm; 2017 Aug; 529(1-2):102-115. PubMed ID: 28642204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel-Loaded Cationic Fluid Lipid Nanodiscs and Liposomes with Brush-Conformation PEG Chains Penetrate Breast Tumors and Trigger Caspase-3 Activation.
    Simón-Gracia L; Scodeller P; Fisher WS; Sidorenko V; Steffes VM; Ewert KK; Safinya CR; Teesalu T
    ACS Appl Mater Interfaces; 2022 Dec; 14(51):56613-56622. PubMed ID: 36521233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer.
    Zhou J; Zhao WY; Ma X; Ju RJ; Li XY; Li N; Sun MG; Shi JF; Zhang CX; Lu WL
    Biomaterials; 2013 May; 34(14):3626-38. PubMed ID: 23422592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.